SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Nyberg Gudrun)
 

Search: WFRF:(Nyberg Gudrun) > The use of pretrans...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003699naa a2200409 4500
001oai:DiVA.org:uu-93118
003SwePub
008050504s2001 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:1960872
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-931182 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:19608722 URI
0247 a https://doi.org/10.1097/00007890-200101150-000132 DOI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Linde, Torbjörnu Uppsala universitet,Institutionen för medicinska vetenskaper,Renal section4 aut
2451 0a The use of pretransplant erythropoietin to normalize hemoglobin levels has no deleterious effects on renal transplantation outcome
264 1b Ovid Technologies (Wolters Kluwer Health),c 2001
338 a print2 rdacarrier
520 a BACKGROUND: The aim of this study was to establish the outcome of renal transplantation in patients given pretransplant erythropoietin (EPO) treatment targeted at reaching a normal hemoglobin concentration (Hb), compared to those given EPO-treatment aimed at maintaining subnormal Hb. METHODS: A total of 416 patients from Scandinavian countries and with renal anaemia were enrolled to examine the effects of increasing Hb from a subnormal level (90-120 g/liter) to a normal level (135-160 g/liter) by EPO treatment. Half of the patients were randomized to have their Hb increased, with the other half randomized to maintain a subnormal Hb. Thirty-two patients from the normal Hb group and 24 patients from the subnormal group received a renal graft during the study period. The outcomes of these transplantations were examined prospectively for 6 months. RESULTS: Preoperative Hb levels were 143+/-17 and 121+/-14 g/liter in the two groups, respectively (P<0.0001). The Hb remained higher in the normal Hb group during the first 2 weeks after transplantation. The percentage of patients requiring postoperative blood transfusions in the normal Hb group was 16%, compared with 50% in the subnormal group (P<0.01). No statistically significant difference in the proportion of functioning grafts or in the serum creatinine levels could be detected. No correlation between EPO treatment and creatinine levels after transplantation was found. The frequency of adverse events was similar in the two groups. CONCLUSIONS: EPO treatment aimed at reaching a normal Hb in renal transplant recipients reduces the postoperative requirement for blood transfusions and has no deleterious effects on kidney graft function.
653 a MEDICINE
653 a MEDICIN
7001 a Ekberg, Henrik4 aut
7001 a Forslund, Terje4 aut
7001 a Furuland, Hansu Uppsala universitet,Institutionen för medicinska vetenskaper,Renal section4 aut
7001 a Holdaas, Hallvard4 aut
7001 a Nyberg, Gudrun4 aut
7001 a Tydén, Gynnaru Karolinska Institutet4 aut
7001 a Wahlberg, Janu Uppsala universitet,Institutionen för kirurgiska vetenskaper,Transplantation Surgery4 aut
7001 a Danielson, Bo G.u Uppsala universitet,Institutionen för medicinska vetenskaper,Renal section4 aut
7102 a Uppsala universitetb Institutionen för medicinska vetenskaper4 org
7730 t Transplantationd : Ovid Technologies (Wolters Kluwer Health)g 71:1, s. 79-82q 71:1<79-82x 0041-1337x 1534-6080
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-93118
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:1960872
8564 8u https://doi.org/10.1097/00007890-200101150-00013

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view